entertainment -WSS

entertainment

author：explore 2025-09-06 04:13:24 - browse：11962

A person reaching for a bottle of lipitor. -- first opinion coverage from STAT — John Moore/Getty Images

The antibiotics crisis is a silent pandemic that threatens to knock modern society back into the medieval age of therapeutic leaches and serum therapy. A world where an accidental scratch in the rose garden can kill.

Why is the supply of new antibiotics so thin, and growing thinner? A high-profile Wall Street Journal article recently highlighted what everyone knows: There is huge need but no market demand.

There are many interrelated causes. Doctors prefer to keep novel antibiotics in reserve, as a last-resort option, limiting sales volumes. Insurance companies like novel antibiotics that prevent costly ICU stays, but they’re used to the cheap price of older generics and balk at any price that allows recoupment of the full cost of development. Low prices and small volumes are a great recipe for insolvency as Achaogen’s experience showed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： ARCH Venture Partners tops STAT's 2023 biotech VC rankings

WSS

ADCs take center stage as promising cancer treatments

Is there really a nursing shortage in the U.S.?

FDA approves RSV monoclonal antibody for infants, toddlers

Biden tests positive for Covid

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Biden tests positive for Covid

focus

entertainment

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Duchenne breakthrough therapy leaves behind pioneering families

Group opposing PBM reform sets lobbying record

Affirmative action in medical school literally saved lives

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Trump demands the U.S. pay no more for drugs than other countries … again

The problems with dementia villages

Drug repurposing or repositioning? The language matters

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

hotspot

Roche drug slashes death risk in early

Questions loom on AstraZeneca cancer drug as safety concerns ebb

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Is there really a nursing shortage in the U.S.?

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Why hospitals are withdrawing from US News rankings

hotspot

focus

focus

Wikipedia